PDT Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

PDT Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$514K	Hold	15,405	–	–	0.03%	396
2026 Q1	$323K	Sell	15,405 -161,408	-91%	-$3.63M	0.02%	459
2025 Q4	$4.07M	Buy	176,813 +20,120	+13%	+$662K	0.26%	137
2025 Q3	$4.71M	Hold	156,693	–	–	0.3%	114
2025 Q2	$5.7M	Buy	156,693 +51,772	+49%	+$1.87M	0.32%	81
2025 Q1	$3.8M	Buy	104,921 +56,062	+115%	+$2.33M	0.27%	118
2024 Q4	$2.06M	Sell	48,859 -17,334	-26%	-$860K	0.18%	197
2024 Q3	$3.68M	Buy	66,193 +13,718	+26%	+$699K	0.33%	71
2024 Q2	$2.16M	Buy	52,475 +1	+0%	+$43	0.2%	186
2024 Q1	$2.45M	Buy	52,474 +4,973	+10%	+$235K	0.23%	153
2023 Q4	$2.27M	Buy	47,501 +14,272	+43%	+$553K	0.25%	125
2023 Q3	$1.18M	Hold	33,229	–	–	0.15%	236
2023 Q2	$1.53M	Buy	+33,229	New	+$1.54M	0.21%	169
2021 Q3	–	Sell	-12,129	Closed	-$1.16M	–	883
2021 Q2	$1.16M	Buy	+12,129	New	+$1.26M	0.08%	350

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

PDT Partners's RARE Position: Q2 2026 in Review

PDT Partners held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 15,405 shares worth $514K. The position accounts for 0.03% of the portfolio, ranked #396.

PDT Partners first reported a position in RARE in Q2 2021 and has held it in 14 quarters since. The position peaked at $5.7M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

PDT Partners held 15,405 shares of Ultragenyx Pharmaceutical worth $514K as of Q2 2026.
PDT Partners left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up 0.03% of PDT Partners's portfolio in Q2 2026, its #396 holding.
PDT Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 14 quarters since.
PDT Partners's Ultragenyx Pharmaceutical position peaked at $5.7M in Q2 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.